CareDx (CDNA)
Runs transplant testing, patient tools, and workflow support around organ health.
Something off on this page? Send us feedback.
Provides molecular surveillance tests for heart, kidney, and lung transplants, supported by patient and digital tools for transplant centers. The business is centered in the US, reports one segment, and is narrowing around testing services plus patient and digital solutions.
Provides precision medicine tools for transplant care, anchored by AlloMap Heart, AlloSure Kidney, AlloSure Heart, HeartCare, and AlloSure Lung. These services monitor rejection or graft injury across heart, kidney, and lung transplant patients.
Adds workflow software, medication-adherence tools, quality tracking, HLA workflow systems, and specialty pharmacy support for transplant centers. Lab products remain part of the portfolio, but a divestiture agreement would shift focus toward testing services and patient and digital solutions.
Operates from a Brisbane, California lab and is concentrated around U.S. transplant centers. Medicare reimbursement, MolDX and Noridian coverage policy, transplant-center adoption, and direct competition from other molecular surveillance providers shape the business.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 2, 2026 | Canaccord Genuity | Target | Target: — | Target: $65 |
| Aug 6, 2026 | BTIG | Reiterate | Rating: —Target: $45 | Target: $60 |
| Aug 3, 2026 | Craig-Hallum | Upgrade | Target: $35 | Target: $64 |
| Jul 31, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $25 | Target: $46 |
| Jul 16, 2026 | BTIG | Reiterate | Rating: —Target: $28 | Target: $45 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $373.6M · Total debt $19.2M · Total assets $533.0M · Shareholders' equity $425.6M
- Revenue
- $131.9M
- Operating income
- $257.0K
- Net income
- $110.6M
No dividends on record.
| Institutions | ≈ 101.91% | 52.72M shares | |
|---|---|---|---|
| 233 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 4.74% | 2.45M shares | |
| 16 holders · as of Sep 15, 2026 | |||
| Strategic holders | 6.32% | 3.27M shares | |
| 1 holder · as of Feb 14, 2022 | |||
| Adds to | 112.97% | ||
51.73M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 112.97%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 9.31% | 4.81M | as of Jun 30, 2026 |
Alger Associates, Inc.Strategic | 6.32% | 3.27M | filed Feb 14, 2022 |
State Street CorpInstitution | 4.77% | 2.47M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.25% | 2.20M | as of Jun 30, 2026 |
Deerfield Management Company, L.P. (Series C)Institution | 3.86% | 2.00M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 4, 2026 | Michael Goldberg | director | −44,700 | $47.06 |
| Aug 5, 2026 | Jeffrey Adam Novack | officer: Secretary and General Counsel | −2,688 | $46.26 |
| Aug 4, 2026 | Christine Cournoyer | director | −16,000 | $46.94 |
| Aug 5, 2026 | George Bickerstaff | director | −20,000 | $46.29 |
| Jul 16, 2026 | Hannah Valantine | director | −28,779 | $36.15 |
- Natera
Closest public rival in transplant dd-cfDNA surveillance
- Insight Molecular Diagnostics
Micro-cap public rival in dd-cfDNA transplant testing
- Thermo Fisher Scientific
One Lambda leads HLA typing and transplant lab products
- QIAGEN
NGS and sample-to-insight tools overlap in HLA typing
- Bio-Rad Laboratories
Clinical-diagnostics tools touch transplant lab workflows
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| CareDx | $56.49 | 0.00% | $2.81B | 26.2 | 51.5 | 6.1 | +52.2% |
| Natera | $392.70 | +0.50% | $53.08B | — | — | 19.6 | +37.7% |
| Insight Molecular Diagnostics | $4.14 | +0.73% | $129.5M | — | — | 77.5 | −53.9% |
| Thermo Fisher Scientific | $658.52 | −0.03% | $244.81B | 35.4 | 25.1 | 5.3 | +10.5% |
| QIAGEN | $43.69 | 0.00% | $9.24B | 23.0 | 17.5 | 4.4 | +0.3% |
| Bio-Rad Laboratories | $379.57 | −0.01% | $10.16B | 45.7 | 36.8 | 3.9 | −0.1% |
| Median | 35.4 | 25.1 | 5.3 | +0.3% |